AT405539T
Lipoxin compounds
Abstract
ACTIVE COMPOUNDS HAVING TROUBLE lipoxins NATURAL, BUT WITH A HALF-LIFE EXPANDED TISSUE. These small molecules are useful for treating diseases vasoconstrictive, inflammatory, myeloid suppressive, cardiovascular, and gastrointestinal.
Term
No projected expiry on record.
- Priority
- Filed
- Granted
- Today
77 members in 11 offices
Priority claims1
| Document | Office | Kind | Date |
|---|---|---|---|
| 7730093 | United States of America | A |
Members77
| Document | Office | Kind | |
|---|---|---|---|
| CA2164951A1 | Canada | A1 | |
| CA2448302A1 | Canada | A1 | |
| WO9429262A1 | World Intellectual Property Organization (WIPO) | A1 | |
| AU7110994A | Australia | A | |
| US5441951A | United States of America | A | |
| EP0703897A1 | European Patent Office (EPO) | A1 | |
| JPH08512023A | Japan | A | |
| US5648512A | United States of America | A | |
| CA2265708A1 | Canada | A1 | |
| WO9811049A1 | World Intellectual Property Organization (WIPO) | A1 | |
| AU4271097A | Australia | A | |
| AU692453B2 | Australia | B2 | |
| EP0927150A1 | European Patent Office (EPO) | A1 | |
| US6048897A | United States of America | A | |
| AU723321B2 | Australia | B2 | |
| JP2001500866A | Japan | A | |
| US2001031882A1 | United States of America | A1 | |
| US6316648B1 | United States of America | B1 | |
| US2002010351A1 | United States of America | A1 | |
| EP0927150B1 | European Patent Office (EPO) | B1 | |
| AT215924T | Austria | T | |
| ATE215924T1 | Austria | T1 | |
| EP1201639A2 | European Patent Office (EPO) | A2 | |
| DE69711894D1 | Germany | D1 | |
| US2002082435A1 | United States of America | A1 | |
| US2002091279A1 | United States of America | A1 | |
| DK0927150T3 | Denmark | T3 | |
| US2002111505A1 | United States of America | A1 | |
| PT927150E | Portugal | E | |
| DE69711894T2 | Germany | T2 | |
| ES2175460T3 | Spain | T3 | |
| EP1201639A3 | European Patent Office (EPO) | A3 | |
| US2003032827A1 | United States of America | A1 | |
| US6569075B2 | United States of America | B2 | |
| CA2265708C | Canada | C | |
| US2003134901A1 | United States of America | A1 | |
| US6620919B2 | United States of America | B2 | |
| US6635776B2 | United States of America | B2 | |
| US6653493B2 | United States of America | B2 | |
| CA2164951C | Canada | C | |
| US6750360B2 | United States of America | B2 | |
| JP2005089472A | Japan | A | |
| JP2005097314A | Japan | A | |
| US6887901B1 | United States of America | B1 | |
| US2005148668A1 | United States of America | A1 | |
| US2006069158A1 | United States of America | A1 | |
| EP1657233A1 | European Patent Office (EPO) | A1 | |
| US7288569B2 | United States of America | B2 | |
| US7294728B2 | United States of America | B2 | |
| JP4060366B2 | Japan | B2 | |
| EP1201639B1 | European Patent Office (EPO) | B1 | |
| AT404522T | Austria | T | |
| ATE404522T1 | Austria | T1 | |
| EP0703897B1 | European Patent Office (EPO) | B1 | |
| AT405539TThis record | Austria | T | |
| ATE405539T1 | Austria | T1 | |
| DE69738918D1 | Germany | D1 | |
| DE69435125D1 | Germany | D1 | |
| PT1201639E | Portugal | E | |
| DK1201639T3 | Denmark | T3 | |
| PT703897E | Portugal | E | |
| DK0703897T3 | Denmark | T3 | |
| ES2312499T3 | Spain | T3 | |
| ES2313715T3 | Spain | T3 | |
| JP2009073810A | Japan | A | |
| EP2058293A1 | European Patent Office (EPO) | A1 | |
| EP2107050A1 | European Patent Office (EPO) | A1 | |
| US2009258945A1 | United States of America | A1 | |
| US2009270498A1 | United States of America | A1 | |
| US7741369B2 | United States of America | B2 | |
| US7825271B2 | United States of America | B2 | |
| JP4625310B2 | Japan | B2 | |
| JP4625311B2 | Japan | B2 | |
| JP2011148815A | Japan | A | |
| JP4819847B2 | Japan | B2 | |
| CA2448302C | Canada | C | |
| US2012277311A1 | United States of America | A1 |
1 legal event, as the office reported them to INPADOC
Events
| Event | Code | |
|---|---|---|
| Publication of translation of european patent specificationUEP | UEP |
Numbers
- Application
- 94920241
Titles2
- German
- LIPOXINVERBINDUNGEN MIT VERLÄNGERTER HALBWERTSZEIT
- English
- Lipoxin compounds with extended half-life
Classification
- CPC, 31
- C07C59/58
- A61P1/00
- A61P1/02
- A61P9/00
- A61P9/08
- A61P9/10
- A61P9/12
- A61P11/00
- A61P11/02
- A61P11/06
- A61P13/02
- A61P13/08
- A61P13/12
- A61P15/00
- A61P17/02
- A61P17/06
- A61P19/02
- A61P19/06
- A61P25/00
- A61P27/16
- A61P29/00
- A61P37/02
- A61P37/08
- A61P43/00
- C07C59/42
- C07C59/46
- C07C59/52
- C07C69/732
- C07C69/734
- C07C69/736
- C07C2601/14
- IPC, 54
- A61K31 11
- A61K31 12
- A61K31 19
- A61K31 191
- A61K31 192
- A61K31 20
- A61K31 202
- A61K31 216
- A61K31 22
- A61K31 23
- A61K31 232
- A61P1 00
- A61P1 02
- A61P11 00
- A61P11 02
- A61P11 06
- A61P13 02
- A61P13 08
- A61P13 12
- A61P15 00
- A61P17 02
- A61P17 06
- A61P19 02
- A61P27 16
- A61P29 00
- A61P37 08
- A61P43 00
- A61P9 00
- A61P9 08
- A61P9 10
- A61P9 12
- C07C229 30
- C07C317 02
- C07C321 02
- C07C47 263
- C07C49 24
- C07C57 52
- C07C59 00
- C07C59 105
- C07C59 11
- C07C59 125
- C07C59 13
- C07C59 42
- C07C59 46
- C07C59 48
- C07C59 52
- C07C59 58
- C07C69 02
- C07C69 58
- C07C69 587
- C07C69 732
- C07C69 734
- C07C69 736
- G01N33 566